{"id":1200,"date":"2019-12-19T09:38:36","date_gmt":"2019-12-19T01:38:36","guid":{"rendered":"https:\/\/clarivate.com\/tw\/2019\/12\/19\/2019%e5%b9%b4%e5%ba%a6%e6%9a%a2%e9%8a%b7%e8%97%a5%e7%89%a9%e9%a0%90%e6%b8%ac%e7%9a%84%e6%9c%80%e6%96%b0%e9%80%b2%e5%b1%95%e5%8f%8a%e5%9b%9e%e9%a1%a7\/?lang=zh-hant"},"modified":"2019-12-19T09:38:36","modified_gmt":"2019-12-19T01:38:36","slug":"expected-blockbusters-a-year-in-progress-3","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/zh\/blog\/expected-blockbusters-a-year-in-progress-3\/","title":{"rendered":"2019\u5e74\u5ea6\u66a2\u92b7\u85e5\u7269\u9810\u6e2c\u7684\u6700\u65b0\u9032\u5c55\u53ca\u56de\u9867"},"content":{"rendered":"<p><em>\u4f5c\u8005\uff1aJoan Tur Torres\uff0c\u79d1\u777f\u552f\u5b89 \u85e5\u7269\u7de8\u8f2f<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>\u4eca\u5e74\u5e74\u521d\uff0c\u79d1\u777f\u552f\u5b89\u767c\u4f48\u4e86<a href=\"https:\/\/clarivate.com\/zh-hant\/news\/news-releases-2019-0321\/\">\u300a2019\u5e74\u6700\u503c\u5f97\u95dc\u6ce8\u7684\u85e5\u7269\u300b\uff08Cortellis Drugs to Watch\uff09<\/a>\uff0c\u5831\u544a\u9810\u6e2c\u4e867\u7a2e\u53ef\u80fd\u57282019\u5e74\u4e0a\u5e02\u3001\u4e26\u65bc5\u5e74\u5167\u6709\u671b\u9054\u5230\u66a2\u92b7\u85e5\u7269\u7b49\u7d1a\u7684\u65b0\u85e5\u3002\u6211\u5011\u96a8\u5f8c\u5831\u5c0e\u4e86\u5176\u4e2d3\u500b\u5df2\u7d93\u7372\u5f97\u6279\u51c6\u7684\u85e5\u7269\uff0c\u5305\u62ec\u6709\u53f2\u4ee5\u4f86\u6700\u6602\u8cb4\u7684\u85e5\u7269Zolgensma\u3002<\/p>\n<p>\u5176\u99184\u500b\u54c1\u7a2e\u9032\u5c55\u5982\u4e0b\uff1aRinvoq (upadacitinib) \u5728\u7f8e\u570b\u6210\u529f\u7372\u51c6\uff1bUltomiris\u5728\u6b50\u76df\u548c\u65e5\u672c\u4e0a\u5e02\uff0c\u4e26\u5728\u7f8e\u570b\u7372\u51c6\u7b2c\u4e8c\u500b\u9069\u61c9\u75c7\uff1bEvrenzo (roxadustat) \u5728\u65e5\u672c\u7372\u51c6\uff0c\u4e26\u5728\u4e2d\u570b\u6210\u529f\u62d3\u5c55\u4e86\u7b2c\u4e8c\u9069\u61c9\u75c7\u3002\u800cPalforzia (AR-101)\u7684\u9032\u5c55\u76f8\u5c0d\u7de9\u6162\uff0c\u5c1a\u8655\u65bcFDA\u5be9\u67e5\u4e2d\u3002<\/p>\n<p>\u672c\u6587\u5c07\u56de\u9867\u4ee5\u4e0a4\u500b\u54c1\u7a2e\u7684\u9032\u5c55\u60c5\u6cc1\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>Rinvoq<\/strong><strong>\u5728\u7f8e\u570b\u7372\u51c6\u7684\u540c\u6642\uff0c\u4e5f\u7372\u5f97\u4e86<\/strong><strong>CHMP<\/strong><strong>\u7684\u6b63\u9762\u652f\u6301<\/strong><\/h3>\n<p>Rinvoq\u662f\u7531AbbVie\u7814\u767c\u7684\u4e00\u7a2e\u53e3\u670dJAK1\u9078\u64c7\u6027\u6291\u5236\u5291\u30022019\u5e748\u6708\u8a72\u7522\u54c1\u5728\u7f8e\u570b\u7372\u51c6\u7528\u65bc\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u7684\u6cbb\u7642\uff0c\u96a8\u5f8c\u4e0d\u4e45\u4fbf\u5728\u7f8e\u570b\u4e0a\u5e02\u3002\u5728III\u671f\u81e8\u5e8a\u8a66\u9a57\uff08SELECT\u8a66\u9a57\uff09\u4e2d\uff0cRinvoq\u7121\u8ad6\u5728\u4e3b\u8981\u81e8\u5e8a\u81e8\u5e8a\u7d42\u9ede\u9084\u662f\u6b21\u8981\u81e8\u7d42\u9ede\u65b9\u9762\uff0c\u5747\u5c55\u73fe\u4e86\u986f\u8457\u7684\u6548\u679c\u3002\u6191\u85c9\u9019\u4e9b\u8cc7\u6599\uff0c\u5c24\u5176\u662f\u512a\u65bc\u300c\u85e5\u738b\u300dHumira\u7684\u7642\u6548\u8cc7\u6599\uff0cRinvoq\u5c07\u5728\u7af6\u722d\u6fc0\u70c8\u7684\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u5e02\u5834\u4e2d\u7372\u5f97\u76f8\u7576\u5927\u7684\u5e02\u5834\u4efd\u984d\u3002<\/p>\n<p>\u76ee\u524d\uff0cRinvoq\u540c\u6642\u4e5f\u5728\u65e5\u672c\u548c\u6b50\u76df\u63a5\u53d7\u5be9\u8a55\u5be9\u6279\uff0c\u4e26\u65bc2019\u5e7410\u6708\u7372CHMP\u7684\u6b63\u9762\u652f\u6301\u3002\u79d1\u777f\u552f\u5b89 <a href=\"https:\/\/clarivate.com\/cortellis\/zh-hant\/solutions\/competitive-intelligence-and-analytics\/\" target=\"_blank\" rel=\"noopener\">Cortellis\u4e0a\u5e02\u6642\u9593\u53ca\u6210\u529f\u7387\u9810\u6e2c\u6a21\u578b (Cortellis-DTSR)<\/a> \u9810\u6e2c\uff0c\u8a72\u85e5\u5728\u5169\u500b\u5730\u5340\u7372\u51c6\u6210\u529f\u7387\u5747\u70ba95%\uff0c\u5f9e\u7372\u51c6\u6642\u9593\u9810\u6e2c\u4f86\u770b\uff0c\u5728\u6b50\u76df\u7684\u7372\u51c6\u6642\u9593\u70ba2019\u5e7412\u6708\uff0c\u65e5\u672c\u7372\u51c6\u6642\u9593\u70ba2020\u5e746\u6708\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>Ultomiris<\/strong><strong>\u5df2\u5728\u591a\u570b\u4e0a\u5e02<\/strong><\/h3>\n<p>Alexion\u7684Ultomiris (ravulizumab) \u5206\u5225\u65bc2019\u5e746\u6708\u548c7\u6708\u7372\u5f97\u65e5\u672c\u548c\u6b50\u76df\u7684\u6279\u51c6\uff0c\u96a8\u5f8c\u4e0d\u4e45\u4fbf\u5728\u4ee5\u4e0a\u5169\u500b\u5730\u5340\u4e0a\u5e02\u3002Ultomiris \u662f\u88dc\u9ad4\u6291\u5236\u5291\uff0c\u4e5f\u662f\u9663\u767c\u6027\u7761\u7720\u6027\u8840\u7d05\u86cb\u767d\u5c3f\u75c7 (PNH) \u9818\u57df\u91cd\u78c5\u70b8\u5f48\u7522\u54c1Soliris\u7684\u4e0b\u4e00\u4ee3\u7522\u54c1\uff08PNH\uff1a\u4e00\u7a2e\u7f55\u898b\u7684\u7372\u5f97\u6027\u8840\u6db2\u75be\u75c5\uff0c\u81f4\u6b7b\u7387\u9ad8\u905450%\uff09\u3002\u8207Soliris\u6bcf2\u5468\u7d66\u85e51\u6b21\u76f8\u6bd4\uff0cUltomiris\u6bcf8\u5468\u7d66\u85e5\u4e00\u6b21\uff0c\u5f88\u5927\u63d0\u9ad8\u4e86\u9806\u61c9\u6027\uff1bUltomiris\u6709\u671b\u6210\u70ba\u8a72\u9818\u57df\u65b0\u7684\u6cbb\u7642\u6a19\u6e96\u3002<\/p>\n<p>\u5176\u4ed6\u9069\u61c9\u75c7\u65b9\u9762\uff0c2019\u5e7410\u6708\uff0cUltomiris\u5728\u7f8e\u570b\u7372\u51c6\u7528\u65bc\u975e\u5178\u578b\u6eb6\u8840\u6027\u5c3f\u6bd2\u7665\u7d9c\u5408\u5f81\u7684\u6cbb\u7642\uff08aHUS\uff1a\u4e00\u7a2e\u6975\u5ea6\u7f55\u898b\u53ef\u5c0e\u81f4\u9010\u6b65\u814e\u8870\u7684\u81f4\u6b7b\u6027\u75be\u75c5\uff09\uff0c\u540c\u6a23\u56e0\u70ba\u9806\u61c9\u6027\u7684\u539f\u56e0\uff0cUltomiris\u5c07\u540c\u6a23\u4ee3\u66ff Soliris\u6210\u70ba\u8a72\u9818\u57df\u7684\u6cbb\u7642\u65b0\u6a19\u6e96\u3002\u76ee\u524d\uff0cUltomiris\u5728\u6b50\u6d32\u548c\u65e5\u672c\u4ecd\u7136\u8655\u65bc\u5be9\u8a55\u4e2d\uff0cCortellis\u9810\u6e2c\u8a72\u7522\u54c1\u5c07\u57282020\u5e74\u4e2d\u65ec\u7372\u51c6\uff0c\u7372\u51c6\u6210\u529f\u7387\u70ba95%\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>Evrenzo<\/strong><strong>\u5728\u65e5\u672c\u7372\u51c6\u7528\u65bc\u6162\u6027\u814e\u75c5\u8ca7\u8840\u7684\u6cbb\u7642\uff0c\u4e26\u5728\u4e2d\u570b\u6210\u529f\u62d3\u5c55\u4e86\u7b2c\u4e8c\u9069\u61c9\u75c7<\/strong><\/h3>\n<p>Evrenzo (roxadustat)\u662f\u7531AstraZeneca\/FibroGen\/Astella\u4e09\u5bb6\u806f\u5408\u958b\u767c\u7684\u7528\u65bc\u6162\u6027\u814e\u75c5\u8ca7\u8840\u7684\u6cbb\u7642\u85e5\u7269\uff0c\u8a72\u7522\u54c1\u4e5f\u662f\u7f3a\u6c27\u8a98\u5c0e\u56e0\u6578-\u812f\u6c28\u9178\u7fa5\u5316\u9176(HIF-PH)\u6291\u5236\u5291\u7684First-in-Class\u85e5\u7269\u30022019\u5e749\u6708\u5728\u65e5\u672c\u7372\u51c6\u7528\u65bc\u300c\u814e\u900f\u6790\u4f9d\u8cf4\u578b\u6162\u6027\u814e\u75c5\u8ca7\u8840\u300d\u7684\u6cbb\u7642\uff0c2019\u5e748\u6708\u8a72\u7522\u54c1\u7684\u9069\u61c9\u75c7\u5728\u4e2d\u570b\u5927\u9678\u6210\u529f\u5730\u5f9e\u300c\u814e\u900f\u6790\u4f9d\u8cf4\u578b\u6162\u6027\u814e\u75c5\u8ca7\u8840\u300d\u62d3\u5c55\u5230\u4e86\u300c\u975e\u814e\u900f\u6790\u4f9d\u8cf4\u578b\u6162\u6027\u814e\u75c5\u8ca7\u8840\u300d\u3002<\/p>\n<p>\u5728\u7f8e\u570b\u548c\u6b50\u76df\uff0c\u300c\u814e\u900f\u6790\u4f9d\u8cf4\u578b\u6162\u6027\u814e\u75c5\u8ca7\u8840\u300d\u548c\u300c\u975e\u814e\u900f\u6790\u4f9d\u8cf4\u578b\u6162\u6027\u814e\u75c5\u8ca7\u8840\u300d\u7684\u9069\u61c9\u75c7\u5747\u5728\u7a4d\u6975\u7533\u5831\u4e2d\u3002\u8207\u7576\u524d\u8a72\u9818\u57df\u5e38\u7528\u7684\u7d05\u7d30\u80de\u751f\u6210\u523a\u6fc0\u56e0\u6578\uff08ESA\uff09\u7684\u81e8\u5e8a\u5c0d\u6bd4\u8cc7\u6599\u986f\u793a\uff0c\u8a72\u85e5\u5177\u6709\u4e0d\u589e\u52a0\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u98a8\u96aa\u7684\u512a\u52e2\u3002Cortellis\u9810\u6e2c\u8a72\u85e5\u5728\u4ee5\u4e0a\u5169\u500b\u5730\u5340\u7684\u7372\u51c6\u6210\u529f\u7387\u70ba90%\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>Palforzia<\/strong><strong>\u7684\u7372\u51c6\u5118\u7ba1\u6709\u6240\u63a8\u5ef6\uff0c\u4f46\u96e2\u7372\u51c6\u66f4\u9032\u4e00\u6b65<\/strong><\/h3>\n<p>Aimmune\u516c\u53f8\u7684Palforzia\u662f\u4e00\u7a2e\u6cbb\u7642\u82b1\u751f\u904e\u654f\u7684\u53e3\u670d\u85e5\u7269\uff0c\u76ee\u524d\u5728\u7f8e\u570bFDA\u63a5\u53d7\u5be9\u8a55\u5be9\u6279\u3002\u8a72\u85e5\u8f03\u539f\u4e0a\u5e02\u6642\u9593\u6709\u6240\u63a8\u9072\uff0c\u4e3b\u8981\u6709\u5169\u500b\u539f\u56e0\uff1a\u4e00\u662f2018\u5e7412\u6708\/2019\u5e741\u6708\u7f8e\u570b\u653f\u5e9c\u505c\u64fa\uff0c\u4e8c\u662fFDA\u6c7a\u5b9a\u5c07Palforzia\u8996\u70ba\u904e\u654f\u6027\u7522\u54c1\u5019\u9078\u85e5\u7269\uff0c\u56e0\u6b64\u8a72\u7522\u54c1\u4e0d\u7b26\u5408\u300c\u5feb\u901f\u901a\u9053\u300d\u548c\u300c\u7a81\u7834\u7642\u6cd5\u300d\u7684\u8cc7\u683c\u3002\u7d93\u8207FDA\u8a0e\u8ad6\uff0c\u8a72\u4e0a\u5e02\u7533\u8acb\u7684\u76ee\u6a19\u671f\u9650\u70ba12\u500b\u6708\uff0c\u9810\u8a08\u958b\u59cb\u65e5\u671f\u70ba2020\u5e741\u6708\u4e0b\u65ec\u30022019\u5e749\u6708\uff0c\u8a72\u7522\u54c1\u7372\u5f97\u904e\u654f\u7522\u54c1\u8aee\u8a62\u59d4\u54e1\u6703(APAC))\u7684\u7a4d\u6975\u5efa\u8b70\uff0cPalforzia\u96e2\u7372FDA\u6279\u51c6\u4e26\u6210\u70ba\u7b2c\u4e00\u500b\u82b1\u751f\u904e\u654f\u7642\u6cd5\u7684\u8ddd\u96e2\u66f4\u9032\u4e00\u6b65\u3002<\/p>\n<p>2019\u5e746\u6708Aimmune\u5411\u6b50\u76df\u905e\u4ea4\u4e86\u4e0a\u5e02\u7533\u8acb\uff0cCortellis\u9810\u6e2c\uff0c\u8a72\u85e5\u7372\u51c6\u6642\u9593\u70ba2020\u5e7410\u6708\uff0c\u7372\u51c6\u6210\u529f\u7387\u70ba95%\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>\u7d50\u8a9e<\/strong><\/h3>\n<p>\u4eca\u5e74\u521d\uff0c\u6211\u5011\u9810\u6e2c\u4e867\u7a2e\u53ef\u80fd\u57282019\u5e74\u4e0a\u5e02\u7684\u65b0\u85e5\uff0c\u90197\u6b3e\u65b0\u85e5\u57282023\u5e74\u7684\u92b7\u552e\u984d\u90fd\u5c07\u9054\u5230\u91cd\u78c5\u7d1a\u5225\u3002\u4ee5\u4e0a\u8a0e\u8ad6\u76844\u500b\u7522\u54c1\u5404\u6709\u7279\u9ede\uff1a\u6191\u85c9\u81e8\u5e8a\u512a\u52e2\u53d6\u5f97\u64c1\u64e0\u5e02\u5834\u7684\u65b0\u85e5\u3001\u6cbb\u7642\u7f55\u898b\u75be\u75c5\u7684\u65b0\u7642\u6cd5\u3001\u4ee5\u53ca\u4f7f\u7528\u5c16\u7aef\u79d1\u5b78\u958b\u767c\u51fa\u7684\u80fd\u5920\u58df\u65b7\u6574\u500b\u65b0\u5e02\u5834\u7684\u65b0\u7522\u54c1\u3002\u9019\u4e9b\u512a\u52e2\u5c07\u70ba\u88fd\u85e5\u696d\u767c\u5c55\u7684\u6700\u65b0\u8da8\u52e2\u63d0\u4f9b\u5f37\u6709\u529b\u7684\u793a\u7bc4\u4f5c\u7528\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>References<\/strong><\/p>\n<ol>\n<li>https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm<\/li>\n<li>https:\/\/www.rinvoqhcp.com\/access-and-support#commercial<\/li>\n<li>https:\/\/news.alexionpharma.com\/press-release\/product-news\/ultomiris-ravulizumab-receives-marketing-authorization-european-commissio<\/li>\n<li>https:\/\/alexionpharma.jp\/press_release\/Press-2019-9-4_Ultomiris_PNH_Japan_Launch_FF.aspx<\/li>\n<li>https:\/\/www.biospace.com\/article\/releases\/alexion-receives-fda-approval-for-ultomiris-ravulizumab-cwvz-for-atypical-hemolytic-uremic-syndrome-ahus-\/<\/li>\n<li>https:\/\/www.prnewswire.com\/news-releases\/evrenzo-roxadustat-tablets-approved-in-japan-for-the-treatment-of-anemia-associated-with-chronic-kidney-disease-in-dialysis-patients-300922278.html<\/li>\n<li>https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019.html<\/li>\n<li>Form 8-K \u2013 Aimmune Therapeutics Inc (16\/01\/19)<\/li>\n<li>https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-treatment-adults-with-moderate-to-severe-active-rheumatoid-arthritis.htm<\/li>\n<li>Form 8-K \u2013 Alexion Pharmaceuticals Inc (21\/12\/18)<\/li>\n<li>https:\/\/www.globenewswire.com\/news-release\/2019\/09\/26\/1921146\/0\/en\/FibroGen-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Anemia-in-Cancer-Patients-Receiving-Chemotherapy.html<\/li>\n<li>https:\/\/www.globenewswire.com\/news-release\/2019\/05\/09\/1821450\/0\/en\/FibroGen-Announces-Positive-Topline-Results-from-Pooled-Safety-Analyses-of-Roxadustat-Global-Phase-3-Program.html<\/li>\n<li>https:\/\/www.businesswire.com\/news\/home\/20190913005515\/en\/FDA-Allergenic-Products-Advisory-Committee-Votes-Support<\/li>\n<li>https:\/\/www.biospace.com\/article\/releases\/aimmune-therapeutics-announces-second-quarter-2019-financial-results-and-provides-operational-highlights\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u4f5c\u8005\uff1aJoan Tur Torres\uff0c\u79d1\u777f\u552f\u5b89 \u85e5\u7269\u7de8\u8f2f &nbsp; \u4eca\u5e74\u5e74\u521d\uff0c\u79d1\u777f\u552f\u5b89\u767c\u4f48\u4e86\u300a2019\u5e74\u6700\u503c\u5f97\u95dc\u6ce8\u7684\u85e5\u7269\u300b\uff08Cortellis Drugs to Watch\uff09\uff0c\u5831\u544a\u9810\u6e2c\u4e867\u7a2e\u53ef\u80fd\u57282019\u5e74\u4e0a\u5e02\u3001\u4e26\u65bc5\u5e74\u5167\u6709\u671b\u9054\u5230\u66a2\u92b7\u85e5\u7269\u7b49\u7d1a\u7684\u65b0\u85e5\u3002\u6211\u5011\u96a8\u5f8c\u5831\u5c0e\u4e86\u5176\u4e2d3\u500b\u5df2\u7d93\u7372\u5f97\u6279\u51c6\u7684\u85e5\u7269\uff0c\u5305\u62ec\u6709\u53f2\u4ee5\u4f86\u6700\u6602\u8cb4\u7684\u85e5\u7269Zolgensma\u3002 \u5176\u99184\u500b\u54c1\u7a2e\u9032\u5c55\u5982\u4e0b\uff1aRinvoq (upadacitinib) \u5728\u7f8e\u570b\u6210\u529f\u7372\u51c6\uff1bUltomiris\u5728\u6b50\u76df\u548c\u65e5\u672c\u4e0a\u5e02\uff0c\u4e26\u5728\u7f8e\u570b\u7372\u51c6\u7b2c\u4e8c\u500b\u9069\u61c9\u75c7\uff1bEvrenzo (roxadustat) \u5728\u65e5\u672c\u7372\u51c6\uff0c\u4e26\u5728\u4e2d\u570b\u6210\u529f\u62d3\u5c55\u4e86\u7b2c\u4e8c\u9069\u61c9\u75c7\u3002\u800cPalforzia (AR-101)\u7684\u9032\u5c55\u76f8\u5c0d\u7de9\u6162\uff0c\u5c1a\u8655\u65bcFDA\u5be9\u67e5\u4e2d\u3002 \u672c\u6587\u5c07\u56de\u9867\u4ee5\u4e0a4\u500b\u54c1\u7a2e\u7684\u9032\u5c55\u60c5\u6cc1\u3002 &nbsp; Rinvoq\u5728\u7f8e\u570b\u7372\u51c6\u7684\u540c\u6642\uff0c\u4e5f\u7372\u5f97\u4e86CHMP\u7684\u6b63\u9762\u652f\u6301 Rinvoq\u662f\u7531AbbVie\u7814\u767c\u7684\u4e00\u7a2e\u53e3\u670dJAK1\u9078\u64c7\u6027\u6291\u5236\u5291\u30022019\u5e748\u6708\u8a72\u7522\u54c1\u5728\u7f8e\u570b\u7372\u51c6\u7528\u65bc\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u7684\u6cbb\u7642\uff0c\u96a8\u5f8c\u4e0d\u4e45\u4fbf\u5728\u7f8e\u570b\u4e0a\u5e02\u3002\u5728III\u671f\u81e8\u5e8a\u8a66\u9a57\uff08SELECT\u8a66\u9a57\uff09\u4e2d\uff0cRinvoq\u7121\u8ad6\u5728\u4e3b\u8981\u81e8\u5e8a\u81e8\u5e8a\u7d42\u9ede\u9084\u662f\u6b21\u8981\u81e8\u7d42\u9ede\u65b9\u9762\uff0c\u5747\u5c55\u73fe\u4e86\u986f\u8457\u7684\u6548\u679c\u3002\u6191\u85c9\u9019\u4e9b\u8cc7\u6599\uff0c\u5c24\u5176\u662f\u512a\u65bc\u300c\u85e5\u738b\u300dHumira\u7684\u7642\u6548\u8cc7\u6599\uff0cRinvoq\u5c07\u5728\u7af6\u722d\u6fc0\u70c8\u7684\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u5e02\u5834\u4e2d\u7372\u5f97\u76f8\u7576\u5927\u7684\u5e02\u5834\u4efd\u984d\u3002 \u76ee\u524d\uff0cRinvoq\u540c\u6642\u4e5f\u5728\u65e5\u672c\u548c\u6b50\u76df\u63a5\u53d7\u5be9\u8a55\u5be9\u6279\uff0c\u4e26\u65bc2019\u5e7410\u6708\u7372CHMP\u7684\u6b63\u9762\u652f\u6301\u3002\u79d1\u777f\u552f\u5b89 Cortellis\u4e0a\u5e02\u6642\u9593\u53ca\u6210\u529f\u7387\u9810\u6e2c\u6a21\u578b (Cortellis-DTSR) \u9810\u6e2c\uff0c\u8a72\u85e5\u5728\u5169\u500b\u5730\u5340\u7372\u51c6\u6210\u529f\u7387\u5747\u70ba95%\uff0c\u5f9e\u7372\u51c6\u6642\u9593\u9810\u6e2c\u4f86\u770b\uff0c\u5728\u6b50\u76df\u7684\u7372\u51c6\u6642\u9593\u70ba2019\u5e7412\u6708\uff0c\u65e5\u672c\u7372\u51c6\u6642\u9593\u70ba2020\u5e746\u6708\u3002 &nbsp; Ultomiris\u5df2\u5728\u591a\u570b\u4e0a\u5e02 Alexion\u7684Ultomiris (ravulizumab) \u5206\u5225\u65bc2019\u5e746\u6708\u548c7\u6708\u7372\u5f97\u65e5\u672c\u548c\u6b50\u76df\u7684\u6279\u51c6\uff0c\u96a8\u5f8c\u4e0d\u4e45\u4fbf\u5728\u4ee5\u4e0a\u5169\u500b\u5730\u5340\u4e0a\u5e02\u3002Ultomiris \u662f\u88dc\u9ad4\u6291\u5236\u5291\uff0c\u4e5f\u662f\u9663\u767c\u6027\u7761\u7720\u6027\u8840\u7d05\u86cb\u767d\u5c3f\u75c7 (PNH)&#8230;<\/p>\n","protected":false},"author":2,"featured_media":5368,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1668],"tags":[],"class_list":["post-1200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-sciences-healthcare"],"acf":[],"lang":"zh","translations":{"zh":1200},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=1200"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1200\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/5368"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=1200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=1200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=1200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}